




RealRate

PHARMACEUTICAL 2022

IGM Biosciences Inc.
Rank 432 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2022

IGM Biosciences Inc.
Rank 432 of 475

The relative strengths and weaknesses of IGM Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IGM Biosciences Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 94% points. The greatest weakness of IGM Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 384% points.

The company's Economic Capital Ratio, given in the ranking table, is -611%, being 334% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	240,747
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,780
Liabilities, Non-Current	25,439
Other Assets	28,885
Other Compr. Net Income	-92
Other Expenses	0
Other Liabilities	0
Other Net Income	-165,164
Property and Equipment	28,495
Research and Development	127,026
Revenues	0
Selling, General and Administrative Expense	38,297

Output Variable	Value in 1000 USD
Assets	298,127
Liabilities	53,219
Expenses	165,323
Stockholders Equity	244,908
Net Income	-330,487
Comprehensive Net Income	-330,533
Economic Capital Ratio	-611%

